The #1 Biotech IPO to Watch in 2021

With TWO reputable scientists leading the way, this under the radar small cap company could be the next biotech growth story on the NASDAQ!   The newly debuted company just closed its approximately $24 million Initial Public Offering (IPO) in September. Being fresh to the NASDAQ makes this new IPO alert one to pay very close attention to as the world begins to learn about what the company is doing!    Already at the forefront of neuroscience research, the company is currently building its drug development pipeline and will be going through the standard IND (Investigational New Drug) application process. It recently announced that they will progress their first compound in collaboration with one of the largest and most well-respected drug discovery and development companies in the world!   A simultaneous revenue stream is expected to launch soon, in the form of providing intravenous ketamine infusions in registered mental health clinics.  Ketamine has been referred to as the FUTURE of depression treatment!    Discover how this small cap biotech player could be the next big name in mental health care treatment!

This email was sent to edwardlorilla1986.paxforex@blogger.com by editor@marketmovingtrends.com MarketMovingTrends, 45 South Park Place, #203, Morristown, NJ 07960 United States   Unsubscribe | Report Spam